South Korea Medical Device Regulatory Update 2026: Expanded Flexibility And Stronger MFDS Oversight

What the Latest Regulatory Changes Mean for Medical Device Manufacturers, RWE, Quality Management, Market Access and Compliance

South Korea is updating its medical device regulatory framework to provide greater flexibility for manufacturers and importers while strengthening regulatory oversight.

Recent amendments to the Medical Device Act and the Regulation on Permission, Notification and Review of Medical Devices introduce important changes affecting Class I medical devices, Real-World Evidence (RWE), translation requirements, quality management conformity assessment and regulatory enforcement.

For global medical device manufacturers, these changes may reduce certain administrative burdens while creating new expectations around regulatory accuracy, quality management and distribution transparency.

Companies planning to enter, maintain or expand their presence in South Korea should review how these developments affect their product approvals, modifications, technical documentation, evidence strategies and lifecycle management.

Why South Korea's Medical Device Regulatory Changes Matter

South Korea is an important medical technology market, with the Ministry of Food and Drug Safety (MFDS) overseeing medical device safety, quality and regulatory compliance.

As medical technologies continue to evolve, manufacturers increasingly manage:

• Advanced medical devices
• Software and digital health technologies
• Innovative devices
• Complex product modifications
• Real-world clinical data
• International technical documentation
• Quality management requirements

The latest amendments are intended to improve regulatory efficiency while maintaining appropriate safety and quality controls.

For manufacturers, the key message is clear: greater flexibility does not mean reduced responsibility for compliance.

Who Should Pay Attention?

The changes are relevant to companies manufacturing, importing, distributing or maintaining medical devices in South Korea.

Companies should assess applicability based on device classification, approval status, product changes, regulatory pathway and market activities.

Class I Medical Devices: Six-Month Transition Period

One of the important changes provides additional flexibility for Class I medical devices.

Manufacturers and importers may continue supplying products manufactured under the previous approval for up to six months after a change is approved, subject to applicable requirements.

This transition period may help companies manage:

• Existing inventory
• Manufacturing changes
• Updated approvals
• Packaging and labeling
• Importer coordination
• Distribution planning

Additional time can make regulatory transitions more manageable and reduce potential disruption to supply.

However, companies should establish clear controls for determining which products remain eligible for supply during the transition period and when updated requirements become applicable.

Real-World Evidence Gets a Broader Role

Another significant development is the expanded role of Real-World Evidence (RWE).

RWE can now support applications involving modifications to existing medical devices, broadening its potential use beyond a limited range of innovative device categories.

This may provide manufacturers with another evidence option when supporting eligible product changes.

Potential RWE sources include:

• Post-market surveillance data
• Clinical-use information
• Patient outcomes
• Device performance data
• Registries
• Healthcare data
• Real-world clinical experience

The usefulness of RWE depends on the quality, relevance, reliability and scientific validity of the evidence.

Manufacturers should therefore develop a structured RWE strategy rather than simply collecting large amounts of market data.

What RWE Means for Product Modifications

For established medical devices, manufacturers may have years of real-world performance information available.

This can potentially include:

• Long-term performance data
• Complaint information
• Post-market trends
• Clinical experience
• Device utilization data
• Registry information

The expanded RWE approach may allow suitable real-world information to contribute to regulatory strategies for eligible modifications.

However, RWE should be scientifically justified and assessed alongside other applicable technical, clinical and regulatory evidence.

Simplified Translation Requirements

The amendments also provide greater flexibility for supporting documents prepared in languages other than Korean.

Notarized translations are no longer required in applicable circumstances where a standard translation and confirmation of accuracy may be sufficient.

This may reduce administrative work for international manufacturers managing documentation from:

• Global headquarters
• Manufacturing sites
• Testing laboratories
• Clinical organizations
• Quality departments
• International suppliers

Although formal notarization requirements may be reduced, companies should continue to ensure that translations are accurate, complete, consistent and traceable.

Quality Management and MFDS Oversight

The amendments also strengthen regulatory oversight through measures including QM conformity assessment fees and stronger enforcement powers.

Quality management therefore remains a critical part of South Korean medical device compliance.

Manufacturers should maintain effective controls covering:

• Quality management procedures
• Manufacturing controls
• Design controls
• Supplier management
• Change control
• Complaint handling
• Corrective and preventive actions
• Post-market surveillance
• Document control

Companies should also review regulatory information carefully before submission.

The strengthened enforcement framework increases the importance of ensuring that technical documentation, regulatory applications and supporting information are accurate and free from misleading or false information.

Distribution Transparency

The updated framework also introduces measures intended to improve transparency across medical device distribution practices.

Manufacturers and importers should consider compliance across the complete product lifecycle:

Manufacturing → Import → Storage → Distribution → Supply → Use → Post-Market Monitoring

Important areas may include:

• Product traceability
• Distribution records
• Importer responsibilities
• Distributor controls
• Complaint management
• Post-market surveillance
• Regulatory reporting

Stronger distribution controls can help companies respond efficiently to quality issues, regulatory requests and post-market events.

2026 South Korea Medical Device Compliance Checklist

Existing Products and Product Changes

The amendments are particularly relevant to manufacturers managing existing devices.

Changes may involve:

• Design
• Materials
• Components
• Software
• Manufacturing processes
• Performance
• Labeling
• Packaging
• Suppliers

Each change should be evaluated for its potential effect on safety, performance, clinical evidence, technical documentation, quality systems and regulatory status.

Where applicable, manufacturers should also determine whether RWE can support the regulatory justification.

Practical South Korea Regulatory Roadmap

A practical implementation approach can include:

1. Identify affected products and approvals.
2. Confirm device classification.
3. Assess Class I products for transition-period applicability.
4. Review current and planned product modifications.
5. Evaluate whether RWE can support eligible applications.
6. Assess available real-world data.
7. Review technical and clinical documentation.
8. Evaluate updated translation requirements.
9. Confirm quality management readiness.
10. Verify regulatory information and supporting evidence.
11. Review distribution and traceability controls.
12. Strengthen post-market surveillance.
13. Update change-control procedures.
14. Monitor ongoing MFDS regulatory developments.

The objective should be to establish a flexible, risk-based and lifecycle-focused regulatory strategy.

Business Benefits of Strong Regulatory Management

Common Compliance Challenges

Manufacturers may face:

• Unclear applicability of new requirements
• Incomplete technical documentation
• Insufficient RWE strategy
• Poor-quality real-world data
• Translation inconsistencies
• Weak quality management controls
• Inadequate change control
• Distribution transparency gaps
• Inconsistent regulatory information
• Insufficient post-market surveillance

Addressing these issues proactively can help reduce regulatory uncertainty and avoid unnecessary market-access delays.

Frequently Asked Questions

1. What has South Korea changed for medical device manufacturers?

The amendments provide greater flexibility in areas including Class I device transitions, RWE and translation requirements while strengthening quality and regulatory oversight.

2. What is the six-month transition period?

Applicable manufacturers and importers may continue supplying certain products manufactured under the previous approval for up to six months following an approved change.

3. Can RWE support medical device modifications?

Yes. The amended framework expands the potential use of RWE for applications involving modifications to existing medical devices.

4. Are notarized translations still required?

In applicable circumstances, notarized translations are no longer required where a standard translation and confirmation of accuracy may be sufficient.

5. Does the update affect quality management?

Yes. The changes introduce QM conformity assessment fees and reinforce quality management compliance expectations.

6. Does MFDS have stronger enforcement powers?

The amended Medical Device Act strengthens enforcement measures, including actions involving false information.

7. What does this mean for distributors?

The changes increase focus on transparency across medical device distribution, making traceability and appropriate distribution controls increasingly important.

8. Should existing products be reassessed?

Manufacturers should review existing approvals, product modifications, technical documentation and quality systems to determine how the updated requirements affect their products.

Conclusion

South Korea's latest medical device regulatory amendments represent an important development for manufacturers and importers.

The changes provide greater flexibility for Class I devices, broader opportunities to use Real-World Evidence and simplified translation processes, while strengthening expectations around quality management, regulatory accuracy, enforcement and distribution transparency.

For manufacturers, the priority should be to balance regulatory flexibility with strong compliance controls.

Companies should review their product portfolios, modification strategies, RWE capabilities, technical documentation, quality systems and distribution processes.

A proactive and lifecycle-focused approach can help medical device companies take advantage of regulatory efficiencies while maintaining readiness for evolving MFDS expectations.

How Maven Regulatory Solutions Can Help

Maven Regulatory Solutions can support medical device companies with:

• South Korea MFDS regulatory assessments
• Medical device market-entry strategies
• Device classification assessments
• Technical documentation review
• Product modification assessments
• Real-World Evidence strategy
• Quality management compliance
• Regulatory submission support
• Post-market regulatory support
• Lifecycle management
• Regulatory intelligence

Our approach helps manufacturers understand regulatory changes, identify compliance gaps and develop practical strategies for successful South Korean market access.